TRANEXAMIC ACID PLUS OXYTOCIN PROPHYLAXIS IN REDUCING BLOOD LOSS AND PREVENTING POSTPARTUM HEMORRHAGE DURING CESAREAN SECTION

Arzoo Gul Bangsah, Sajida Riaz, Zubaida Akhtar, Talat Naz, Jamila M Naib
Department of Obstetrics and Gynaecology, Khyber Teaching Hospital, Peshawar - Pakistan

ABSTRACT
Objective: To find the efficacy of prophylactic tranexamic acid and Oxytocin in preventing postpartum hemorrhage during cesarean section as compared to uterotonic alone.

Materials and Methods: A randomized clinical trial that was single-center, double-blind placebo-controlled was conducted in the Department of Obstetrics and Gynaecology, Khyber Teaching Hospital, between 1st July 2021 to 31st December 2021. A total of 280 patients undergoing cesarean section were randomized to group A receiving tranexamic acid and uterotonic (oxytocin) and control group B having placebo and uterotonic(oxytocin) within three minutes of delivery of the baby. Blood loss after the cesarean section was calculated from blood volume and pre and post-operative hematocrit. The main outcome of the study was to establish the efficacy of tranexamic acid in decreasing the number of women with calculated estimated blood loss > 1000 ml. Secondary outcomes included differences in mean calculated blood loss, peripartum change in hematocrit, and postoperative blood transfusion in both groups. Data was analyzed by statistical package for social sciences (SPSS) version 23.0. Mean and standard deviation were calculated for numerical data and percentages, and frequencies for categorical variables. To see the effects of modifiers, post stratified t-test was used. P-value <0.05 was considered statistically significant.

Results: Both the groups were comparable for maternal age (28.4±4.5, 28.8±4.9) gestational age (37.71±1.61, 37.70±1.56), and parity (1.79±1.5, 2±1.6). Tranexamic acid significantly reduced the number of women with estimated calculated blood loss of > 1000 ml in group A to 10%(n=14) as compared to 18.6%(n=26) in group B (p-value<0.005). Secondary outcomes like mean calculated blood loss and postoperative blood transfusion were statistically insignificant between the two groups.

Conclusion: Pregnant women who received prophylactic uterotonic agents and tranexamic acid treatment within three minutes of cesarean delivery, resulted in a lesser number of women with calculated estimated blood loss > 1000 ml than placebo.

Key Words: Primary postpartum hemorrhage, Tranexamic acid, Cesarean section, Blood loss.

INTRODUCTION
Primary post-partum hemorrhage remains the leading cause of maternal mortality and morbidity. Despite improvements in antenatal and obstetric care, it has traditionally been defined as blood loss of > 500ml after vaginal delivery and > 1000ml during cesarean delivery of the baby. As per the World Health Organization 2012 report, nearly 100000 mothers die every year because of PPH and 99% of these deaths occur in middle-low-income countries. In Pakistan, the prevalence of PPH is 34% leading to considerable morbidity and mortality of parturient mothers.

The practice of cesarean delivery is increasing day by day with rates rising to 25-30%. Globally, studies have shown that blood loss during vaginal delivery is considerably lesser as compared to cesarean section. French studies showed that cesarean deliveries were associated with > 1000 mL blood loss in 11.6% of cases.

World Health Organization (WHO) recommends prophylactic uterotonics such as oxytocin to prevent PPH. But PPH is unpredictable and the majority of the cases occur in the absence of risk factors. Uterotonic(oxytocin) alone might not effectively prevent PPH, secondary to other causes.

Following the results from the World Maternal Antifibrinolytic Trial (WOMAN Trial) which established the
therapeutic efficacy of tranexamic acid in reducing bleeding-related mortality in parturient mothers, the WHO has recommended the use of Tranexamic Acid (TXA) for the treatment of PPH.  

An antifibrinolytic drug, tranexamic acid acts on plasminogen molecules by blocking their lysine binding sites. After the delivery of the baby, tranexamic acid arrests bleeding by stopping the fibrinolytic system that is activated during placental separation. During placental delivery fibrinolytic system is activated, and the effect persists for 6-10 hours postnatally, causing more bleeding that can be dealt with effectively by administering tranexamic acid. TXA not only reduces postpartum blood loss but also the need for blood transfusion and anemia. The Royal College of Obstetricians and Gynaecologists currently recommends considering the use of prophylactic TXA only in women at high risk for PPH undergoing cesarean section (CS). However, there is limited evidence for definitive recommendations of prophylactic TXA use in women of all risk profiles undergoing cesarean section. Further high-quality randomized trials are required to confirm the safety and efficacy of TXA in preventing PPH in all women undergoing cesarean section.

Our study aim was to evaluate the effectiveness of prophylactic tranexamic acid administration along with conventional oxytocin in reducing calculated blood loss during cesarean section. Locally no such randomized clinical trial, using a validated method for measuring postpartum blood loss has been conducted. We hypothesize that tranexamic acid could be used in conjunction with traditional uterotonic drugs for preventing PPH in women undergoing cesarean delivery. Our study will help in yielding local data on the prophylactic efficacy of tranexamic acid in reducing postpartum blood loss & update the current guidelines on preventing PPH.

**MATERIALS AND METHODS**

A randomized controlled clinical trial was conducted in the Department of Obstetrics and Gynecology, Khyber teaching hospital between 1st July 2021-31 December 2021, after getting approval from the research & ethical review board (814/DME/KMC). A total of 405 patients were enrolled by the non-probability consecutive sampling method. The sample size was calculated using WHO sample size calculator version 2.0 taking 28.0 ± 5.53 mL blood loss in the tranexamic acid group vs. 37.12±8.97ml in the control group, along with a 95% confidence level of significance with 90% power of the test. Pregnant women undergoing elective and emergency cesarean section were screened for eligibility by a research assistant who received training from the lead investigator before the start of the study. Study participants were informed that they could withdraw voluntarily from the trial at any time.

Predesigned proformas were filled out for each patient after taking informed written consent before and after the operation. The proforma included information on age, parity, weight, period of gestation, and an indication of elective and emergency cesarean section. Prenatal and post-natal hemoglobin and hematocrit were also recorded. Women having severe medical disorders, thrombocytopenia, anemia, allergy to tranexamic acid, history of venous thromboembolism, placenta-previa, abortion, and severe pre-eclampsia, failed operative vaginal delivery, retained the second twin were excluded from the study. Eligible patients, who consented were randomly allocated into two groups of 140 each by lottery method. Study group A(n=140) received 1 gm tranexamic acid (available at hospital pharmacy free of cost) intravenously within three minutes of delivery of the baby along with routine 10 IU intravenous oxytocin and control group B(n=140) received routine intravenous 10 IU oxytocin and placebo(10ml normal saline intravenously). The nurse practitioner supervised the randomization process. The anesthetist was instructed to administer oxytocin and tranexamic acid or normal saline/placebo depending on group allocation, followed by two hours of oxytocin infusion as per WHO protocol. Neither the lead investigator and operating obstetrician nor the patient knew about the group allocation. Post-operatively women were transferred from the operating theatre to the post-anesthesia recovery unit where the parturient mothers stayed for one hour before shifting to the postnatal chamber. Preoperative hematocrit was the hematocrit measured within ≤ seven days before delivery. Hematocrit obtained by venous blood sampling on postpartum day 2 was labeled as postoperative hematocrit. Any potential side effects of TXA were recorded during the patient’s stay in the hospital’s post-natal ward.

The main outcome of the study was to find the percentage of the patient in the study and placebo group with a calculated blood loss <1000ml using a validated formula. The imprecision of blood loss estimation during cesarean deliveries using a gravimetric method like pre-weighed pads, suction container volume, and visual estimation, lead us to search for some other validated methods to calculate blood loss. The amount of blood loss in milliliters was calculated by the formula used in a French trial, as calculated estimated blood loss = estimated blood volume × (preoperative hematocrit–postoperative hematocrit/ preoperative hematocrit (where estimated blood volume (mL) = weight (kg) × 85). Secondary outcomes included peripartum change in hematocrit, mean calculated blood loss & postoperative blood transfusion in both groups. Data was analyzed by statistical package for social sciences (SPSS) version-23. Frequencies and percentages were calculated for categorical variables, and mean and standard deviation were calculated for numerical data. To see the effects of modifiers, post stratified t-test was used. P-value <0.05 was considered statistically significant.
RESULTS

Subject characteristics were similar in both groups (statistically insignificant differences between the two groups). The mean age was 28.4±4.5 in Group A and 28.8±4.9 in Group B. Mean parity and gestational age were 1.79±1.5 & 37.71±1.61 respectively in Group A. While group B showed mean parity of 2±1.6 and gestational age of 37.70±1.56. Tranexamic acid significantly reduced the number of women with estimated calculated blood loss of > 1000 ml in group A(10%) as compared to 18.6%(n=26) in group B (p-value<0.005). Blood transfusion on Day 2 was seen in 14 patients in tranexamic acid group A as compared to 20 patients in placebo group B. Mean Calculated estimated blood loss in Tranexamic group A was 626.8±472 ml and 699±489 ml in placebo group B with a mean difference of 73 ml. Peripartum change in hematocrit was statistically insignificant.

DISCUSSION

Globally, cesarean section rates are soaring day by day ranging from 25-40%. Obstetric hemorrhage is one of the most commonly occurring complications with significant maternal mortality and morbidity. The WOMAN trial endorsed the effective role of TXA in treating PPH, during vaginal delivery & cesarean section. Sixteen randomized trials have shown decreased blood loss in pregnant women who receive prophylactic tranexamic acid, during elective cesarean section, excluding emergency cesarean where blood loss is significantly higher.

Table 2 Clinical Outcomes of Trial

<table>
<thead>
<tr>
<th>Clinical Outcomes</th>
<th>Group A (N=140)</th>
<th>Group B (N=140)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main Outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPH=No Of Patients/Total number</td>
<td>14(10%)</td>
<td>26(18.6%)</td>
<td>0.040</td>
</tr>
<tr>
<td>Calculated Blood Loss&gt;1000ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary Outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Calculated blood loss in ml±SD</td>
<td>626.8±472</td>
<td>699±489</td>
<td>0.210</td>
</tr>
<tr>
<td>Mean peripartum change in hematocrit±SD</td>
<td>3.30±2.64</td>
<td>3.38±2.68</td>
<td>0.802</td>
</tr>
<tr>
<td>Additional Uterotonics for excessive bleeding--no/total no. (%)</td>
<td>3(2%)</td>
<td>7(5%)</td>
<td>0.198</td>
</tr>
<tr>
<td>Blood transfusion by day 2</td>
<td>14(10%)</td>
<td>20(14%)</td>
<td>0.272</td>
</tr>
</tbody>
</table>

Fig 1: Randomization & Treatment: CONSORT Flow Diagram
during cesarean section for breech presentation, but the study design and gravimetric method of blood loss calculation differed significantly from our study. A Turkish RCT also endorsed our study results by showing that 2.1% of patients in TXA had postpartum blood loss >1000ml as compared to 5.8% in the placebo group. 

It is important to ascertain the methodology used in different trials for assessing postpartum blood loss during & after cesarean section. Gravimetric methods like suction container volume or weighted pads for measuring postpartum blood loss are imprecise and prone to subjective bias.

To circumvent such methodological flaws, we used a validated formula used in the French trial, for assessing blood loss. The reduction in the proportion of patients having blood loss of >1000ml in the study versus the control group in the TRAAP-2 trial (26.7% vs. 31.5%) is somewhat comparable to our study (10% vs. 18.6%) despite our small sample size. Both studies showed a reduced need for additional uterotonic drugs and blood transfusion in the study versus the control group.

In contrast to our study, a mean difference of 141.6 ml between the study and control group was published in the meta-analysis by Wang et al. Two Iranian studies showed a significant difference (132.7ml) in mean blood loss between tranexamic acid and control groups but used gravimetric methods to calculate blood loss. Similar to these studies, our trial showed that the mean estimated calculated blood loss was 626.8±472 ml in tranexamic acid group A as compared to 699±489ml in placebo or control group B, with a mean difference of 73 ml. Although our mean difference in blood loss between the two groups is not statistically significant as reported in other studies possibly because of methodological differences (timing and dosage of TXA, type of cesarean section) and sample size variation. Nevertheless, the proportion of women undergoing cesarean delivery with calculated blood loss of more than 1000 ml, the need for blood transfusion, and supplementary uterotonic drugs are more or less comparable to the TRAAP-2 trial, employing a similar trial methodology.

The strength of our study is that it was a randomized clinical trial using a validated method to calculate postpartum blood loss. Our trial will contribute to the growing body of research suggesting the use of tranexamic acid along with time-tested uterotonic agents immediately after childbirth to prevent postpartum hemorrhage. Several limitations of the study need to be acknowledged which include the exclusion of anemic and high-risk obstetric women and the inclusion of emergency cesarean section in the trial. Extrapolation from single-center & small sample-sized studies would be possible only if multi-center and larger sample-size-driven studies are planned and executed across the globe for unified consensus and recommendation.

CONCLUSIONS

Prophylactic TXA & oxytocin should be considered in women undergoing cesarean section to reduce blood loss. Further studies are required to validate the role of TXA in women at high risk of PPH. Ideal dosing and timing of TXA administration, its cost-effectiveness, and adverse effect profile remain important associations to be explored in the future.

REFERENCES


CONFLICT OF INTEREST: Authors declare no conflict of interest

GRANT SUPPORT AND FINANCIAL DISCLOSURE: NIL

AUTHOR’S CONTRIBUTION

Following authors have made substantial contributions to the manuscript as under

Bangash AG: Concept, Critical appraisal, and Discussion Writing
Riaz S: Data collection, compilation of results, formatting of the article
Akhtar Z: Data Collection, Manuscript writing
Naz T: Manuscript Writing, Bibliography
Naib JM: Supervision, Critical appraisal

Authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

This work is Licensed under a Creative Commons Attribution-(CC BY 4.0)